About Luke
Luke Jedynak is a Senior Associate in the firm’s corporate and commercial team. He works for a diverse range of commercial clients, including ASX 100 companies, private equity firms and large privately-held businesses.
Luke assists his clients on a diverse range of commercial matters, including large-scale mergers and acquisitions and special situations as well as smaller, strategic investments. Luke is known for his smart, commercial and outcomes-focused approach to transactions.
Luke joined Arnold Bloch Leibler in 2016 and was admitted to practice in 2017. He has undergraduate degrees in law and chemical engineering as well as a master of laws from the University of Melbourne. Luke is currently undertaking a part-time MBA at the Melbourne Business School.
Between February 2021 and May 2022, Luke was a senior advisor to the Commonwealth Treasurer, the Hon Josh Frydenberg. Luke was responsible for providing advice directly to the Treasurer in relation to corporate law and financial services related matters, including a review of corporate control transactions in Australia, the Treasurer’s powers under Australia’s foreign investment regime and reforms of Australia’s employee share ownership rules. During this time, Luke worked closely with senior executives within the Commonwealth Treasury and a number of federal regulators, including the Australian Securities & Investments Commission and Australian Competition & Consumer Commission.
Experience
Luke has advised on a range of matters, including:
-
Acted as Australian counsel for the new major equity owners of GenesisCare, one of Australia’s largest providers of cancer services, in connection with a debt-for-equity swap as part of GenesisCare’s US$2.1 billion restructure
-
Strategic investment by Macquarie Capital Principal Finance, a division of Macquarie Bank, in Envest, the Australian based insurance investment and distribution business of the Ardonagh Group, giving Macquarie a 15% interest and Envest an enterprise value of more than A$1 billion
-
Sale by European private equity firm JAB to EQT Group of VetPartners, Australia and New Zealand’s largest provider of veterinary and animal health services
-
Sale by Apotex International of its 50% interest in Arrotex, Australia’s largest generic pharmaceutical company
-
The A$1.35 billion sale by 26 Australian industry super funds of ME Bank to Bank of Queensland Ltd
- Nufarm’s divestment of its Latin American business to Sumitomo Chemical for A$1.18 billion
- Sale of RYCO Hydraulics by its CEO and major shareholder to Italian based Manuli Rubber Industries
- The merger of Apotex Australia and Arrow Pharmaceuticals to form Australia’s largest generic pharmaceuticals company
- Acting for the minority shareholders of Australian wagering company BetEasy in relation to the sale of their remaining interest in BetEasy to Canadian gaming company The Stars Group and Stars’ subsequent merger with Irish bookmaker Flutter Entertainment plc, and
- Acting for Krispy Kreme Doughnut Corporation in relation to its acquisition of the Krispy Kreme Australia and New Zealand franchise business from its founding shareholders.
